Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Pharmacodynamic monitoring of mycophenolic acid therapy: Improved LC-MS/MS method for measuring inosin-5'-monophosphate dehydrogenase activity.

Weißbarth G, Wiesen MHJ, Fietz C, Streichert T, Ehren R, Weber LT, Müller C.

Ther Drug Monit. 2019 Aug 16. doi: 10.1097/FTD.0000000000000688. [Epub ahead of print]

PMID:
31425491
2.

Generation and validation of a limited sampling strategy to monitor mycophenolic acid exposure in children with nephrotic syndrome.

Benz MR, Ehren R, Kleinert D, Müller C, Gellermann J, Fehrenbach H, Schmidt H, Weber LT.

Ther Drug Monit. 2019 Aug 14. doi: 10.1097/FTD.0000000000000671. [Epub ahead of print]

PMID:
31425441
3.

A newly established clinical registry of minimal change disease and focal and segmental glomerulosclerosis in Germany.

Völker LA, Ehren R, Grundmann F, Benzing T, Weber LT, Brinkkötter PT.

Nephrol Dial Transplant. 2019 Apr 21. pii: gfz046. doi: 10.1093/ndt/gfz046. [Epub ahead of print] No abstract available.

PMID:
31006002
4.

The quest for optimal control of relapses in children with nephrotic syndrome.

Schijvens AM, Ehren R, Weber LT, Schreuder MF.

Kidney Int. 2019 Mar;95(3):717. doi: 10.1016/j.kint.2019.01.002. No abstract available.

PMID:
30784663
5.

Discontinuation of maintenance therapy in frequently relapsing nephrotic syndrome
.

Vogd J, Hackl A, Habbig S, Lechner F, Akarkach A, Weber LT, Ehren R.

Clin Nephrol. 2019 Jan;91(1):25-31. doi: 10.5414/CN109532.

PMID:
30369402
6.

Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil versus prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study).

Ehren R, Benz MR, Doetsch J, Fichtner A, Gellermann J, Haffner D, Höcker B, Hoyer PF, Kästner B, Kemper MJ, Konrad M, Luntz S, Querfeld U, Sander A, Toenshoff B, Weber LT; Gesellschaft für Pädiatrische Nephrologie (GPN).

BMJ Open. 2018 Oct 10;8(10):e024882. doi: 10.1136/bmjopen-2018-024882.

7.

Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring.

Hackl A, Becker JU, Körner LM, Ehren R, Habbig S, Nüsken E, Nüsken KD, Ebner K, Liebau MC, Müller C, Pohl M, Weber LT.

Pediatr Nephrol. 2018 Apr;33(4):619-629. doi: 10.1007/s00467-017-3846-6. Epub 2017 Nov 25.

PMID:
29177628
8.

Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS.

Hackl A, Ehren R, Kirschfink M, Zipfel PF, Beck BB, Weber LT, Habbig S.

Pediatr Nephrol. 2017 Jun;32(6):1081-1087. doi: 10.1007/s00467-017-3612-9. Epub 2017 Feb 20. Review.

PMID:
28220235
9.

Effect of mycophenolic acid in experimental, nontransplant glomerular diseases: new mechanisms beyond immune cells.

Hackl A, Ehren R, Weber LT.

Pediatr Nephrol. 2017 Aug;32(8):1315-1322. doi: 10.1007/s00467-016-3437-y. Epub 2016 Jun 16. Review.

PMID:
27312386
10.

Extrarenal Manifestations in Shigatoxin-associated Haemolytic Uremic Syndrome.

Matthies J, Hünseler C, Ehren R, Volland R, Körber F, Hoppe B, Weber LT, Habbig S.

Klin Padiatr. 2016 Jul;228(4):181-8. doi: 10.1055/s-0042-108444. Epub 2016 Jun 13.

PMID:
27294341
11.

Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference?

Hackl Á, Cseprekál O, Gessner M, Liebau MC, Habbig S, Ehren R, Müller C, Taylan C, Dötsch J, Weber LT.

Ther Drug Monit. 2016 Apr;38(2):274-9. doi: 10.1097/FTD.0000000000000258.

PMID:
26488204
12.

Design and evaluation of a human immunodeficiency virus type 1 RNA assay using nucleic acid sequence-based amplification technology able to quantify both group M and O viruses by using the long terminal repeat as target.

de Baar MP, van der Schoot AM, Goudsmit J, Jacobs F, Ehren R, van der Horn KH, Oudshoorn P, de Wolf F, de Ronde A.

J Clin Microbiol. 1999 Jun;37(6):1813-8.

Supplemental Content

Support Center